Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LET-Optimized IMPT and Chemotherapy for Anal Canal Squamous Cell Carcinoma
NCT03690921Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2018
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in anal canal squamous cell carcinoma (SCCA), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Acute grade 3 or greater gastrointestinal, genitourinary and hematologic toxicities at 12 weeks. Started Nov 2018; status: completed.
02
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT03690921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690921.